UPDATE 鈥� Climb Bio to Present at Upcoming September 2025 Investor Conferences
Climb Bio (Nasdaq: CLYM), a clinical-stage biotechnology company focused on immune-mediated disease therapeutics, has announced its participation in four major investor conferences in September 2025.
The company will participate in the Cantor Global Healthcare Conference (Sept 5), Baird Global Healthcare Conference (Sept 9), Morgan Stanley Annual Global Healthcare Conference (Sept 10), and Stifel Virtual Immunology and Inflammation Forum (Sept 16). Most events will feature fireside chats or presentations along with one-on-one investor meetings.
Live webcasts will be available through Climb Bio's investor relations website, with replays accessible for 30 days after each event.
Climb Bio (Nasdaq: CLYM), una societ脿 biotecnologica in fase clinica specializzata in terapie per malattie a mediazione immunitaria, ha annunciato la sua partecipazione a quattro importanti conferenze per investitori nel settembre 2025.
L鈥檃zienda sar脿 presente al Cantor Global Healthcare Conference (5 settembre), al Baird Global Healthcare Conference (9 settembre), al Morgan Stanley Annual Global Healthcare Conference (10 settembre) e al Stifel Virtual Immunology and Inflammation Forum (16 settembre). La maggior parte degli eventi prevedr脿 interviste in formato fireside chat o presentazioni, oltre a incontri individuali con gli investitori.
I webcast in diretta saranno disponibili sul sito degli investor relations di Climb Bio e le repliche potranno essere visionate per 30 giorni dopo ciascun evento.
Climb Bio (Nasdaq: CLYM), una compa帽铆a biotecnol贸gica en fase cl铆nica enfocada en terapias para enfermedades mediadas por el sistema inmunitario, ha anunciado su participaci贸n en cuatro importantes conferencias para inversores en septiembre de 2025.
La empresa asistir谩 al Cantor Global Healthcare Conference (5 de septiembre), al Baird Global Healthcare Conference (9 de septiembre), al Morgan Stanley Annual Global Healthcare Conference (10 de septiembre) y al Stifel Virtual Immunology and Inflammation Forum (16 de septiembre). La mayor铆a de los eventos incluir谩n charlas tipo fireside o presentaciones, adem谩s de reuniones individuales con inversores.
Habr谩 retransmisiones en directo disponibles a trav茅s del sitio web de relaciones con inversores de Climb Bio, con repeticiones accesibles durante 30 d铆as tras cada evento.
Climb Bio (Nasdaq: CLYM), 氅挫棴 毵り皽 歆堩櫂 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠 氚旍澊鞓ろ厡韥� 旮办梾鞚� 2025雲� 9鞗� 欤检殧 韴瀽鞛� 旎嵓霟办姢 雱� 瓿踌棎 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
须岇偓电� Cantor Global Healthcare Conference(9鞗� 5鞚�), Baird Global Healthcare Conference(9鞗� 9鞚�), Morgan Stanley Annual Global Healthcare Conference(9鞗� 10鞚�), Stifel Virtual Immunology and Inflammation Forum(9鞗� 16鞚�)鞐� 彀胳劃頃� 鞓堨爼鞛呺媹雼�. 雽�攵�攵勳潣 頄夓偓鞐愳劀電� 韺岇澊鞏挫偓鞚措摐 毂勴寘 霕愲姅 頂勲爤鞝犿厡鞚挫厴瓿� 頃粯 韴瀽鞛愳檧鞚� 鞚茧寑鞚� 氙疙寘鞚� 歆勴枆霅╇媹雼�.
霛检澊敫� 鞗轨簮鞀ろ姼電� Climb Bio鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞝滉车霅橂┌, 臧� 頄夓偓 頉� 30鞚缄皠 雼れ嫓氤搓赴臧� 臧�電ロ暕雼堧嫟.
Climb Bio (Nasdaq: CLYM), une entreprise biotechnologique en phase clinique sp茅cialis茅e dans les traitements des maladies 脿 m茅diation immunitaire, a annonc茅 sa participation 脿 quatre grandes conf茅rences investisseurs en septembre 2025.
La soci茅t茅 participera 脿 la Cantor Global Healthcare Conference (5 septembre), 脿 la Baird Global Healthcare Conference (9 septembre), 脿 la Morgan Stanley Annual Global Healthcare Conference (10 septembre) et au Stifel Virtual Immunology and Inflammation Forum (16 septembre). La plupart des 茅v茅nements comprendront des entretiens de type fireside chat ou des pr茅sentations, ainsi que des rencontres individuelles avec des investisseurs.
Des webcasts en direct seront disponibles sur le site relations investisseurs de Climb Bio, avec des rediffusions accessibles pendant 30 jours apr猫s chaque 茅v茅nement.
Climb Bio (Nasdaq: CLYM), ein biotechnologisches Unternehmen in klinischer Phase mit Schwerpunkt auf Therapien f眉r immunvermittelte Erkrankungen, hat seine Teilnahme an vier wichtigen Investorenkonferenzen im September 2025 angek眉ndigt.
Das Unternehmen wird an der Cantor Global Healthcare Conference (5. Sept.), der Baird Global Healthcare Conference (9. Sept.), der Morgan Stanley Annual Global Healthcare Conference (10. Sept.) und dem Stifel Virtual Immunology and Inflammation Forum (16. Sept.) teilnehmen. Bei den meisten Veranstaltungen sind Fireside-Chats oder Pr盲sentationen sowie Einzelgespr盲che mit Investoren geplant.
Live-Webcasts sind 眉ber die Investor-Relations-Website von Climb Bio verf眉gbar; Wiederholungen stehen jeweils 30 Tage nach der Veranstaltung zum Abruf bereit.
- None.
- None.
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below.聽
Cantor Global Healthcare Conference
Location: New York, NY
Format: Fireside chat and one-on-one investor meetings
Date: Friday, September 5, 2025
Time: 10:55 a.m. ET
Baird Global Healthcare Conference
Location: New York, NY
Format: Fireside chat and one-on-one investor meetings
Date: Tuesday, September 9, 2025
Time: 4:20 PM p.m. ET
Morgan Stanley Annual Global Healthcare Conference
Location: New York, NY
Format: One-on-one meetings only
Date: Wednesday, September 10, 2025
Stifel Virtual Immunology and Inflammation Forum
Location: Virtual
Format: Presentation and one-on-one investor meetings
Date: Tuesday, September 16, 2025
Time: 10:30 a.m. ET
The live webcasts will be accessible via the 鈥淚nvestors and News鈥� section of the Climb Bio website: . Webcast replays will be available on the Climb Bio website beginning approximately two hours after each webcast event and will be archived for at least 30 days.
About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company鈥檚 pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit .
Investors and Media
Carlo Tanzi, Ph.D.
Kendall Investor Relations
[email protected]
FAQ
When is Climb Bio (CLYM) presenting at the Cantor Global Healthcare Conference 2025?
How can investors access Climb Bio's (CLYM) September 2025 conference presentations?
Which investor conferences will Climb Bio (CLYM) attend in September 2025?
What is Climb Bio's (CLYM) main business focus?
